Related by context. All words. (Click for frequent words.) 69 STRIDE PD 69 Prostate AdenoCarcinoma Treatment 64 Phase Ib II 64 riociguat 63 phase Ib 63 MAGE A3 ASCI 63 HCV SPRINT 63 AVOREN 63 LUX Lung 62 HCV RESPOND 2 62 velafermin 62 PLCO 62 Elocalcitol 62 relapsed MM 62 Aggressive Reduction 62 differentiated thyroid 62 Adjuvant Treatment 62 YONDELIS 61 ANCHOR trial 61 Cholesterol Levels SPARCL 61 RE LY 61 metastatic castration resistant 61 Phase IIIb clinical 61 olaparib 61 adecatumumab 61 pertuzumab 61 cediranib 61 Randomized Phase 61 Dasatinib 61 BRIM3 61 EchoCRT 61 trastuzumab DM1 61 eprotirome 61 recurrent glioma 61 subgroup analyzes 61 Hepatocellular Carcinoma HCC 61 Pirfenidone 61 sorafenib Nexavar 61 Degarelix 61 PSMA ADC 61 secondary efficacy endpoints 61 iPrEx 61 PROSTVAC TM 61 ILLUMINATE 61 ACTIVE W 60 Neoadjuvant 60 BCIRG 60 mRCC 60 Advanced Renal Cell 60 ACTEMRA TM 60 Traficet EN 60 tanespimycin 60 PIX# [002] 60 Enzastaurin 60 ixabepilone 60 BRIM2 60 AIM HIGH 60 RE LY ® 60 recurrent glioblastoma multiforme 60 Sorafenib HCC Assessment 60 metastatic colorectal 60 INCB# [001] 60 Dose escalation 60 CIMZIA ™ 60 evaluating mipomersen 60 CAMMS# 60 figitumumab 60 ToGA 60 enzastaurin 60 temsirolimus 60 Phase 2a trial 60 castrate resistant prostate cancer 60 biliary tract cancer 60 Randomized Phase II 60 Vandetanib 60 sunitinib malate 60 pharmacodynamic effects 60 castration resistant prostate cancer 60 Prostate Lung Colorectal 59 adjuvant GIST 59 ONTARGET 59 chemoprevention trials 59 HER2 positive metastatic breast 59 nab paclitaxel 59 Phase Ib study 59 ADVANCE PD 59 efficacy endpoint 59 metastatic GIST 59 Lung Cancer Trial 59 atrasentan 59 NSABP 59 Intervention Trial GAIT 59 HuMax EGFr 59 gefitinib Iressa 59 Velcade bortezomib 59 paclitaxel Taxol R 59 Prostate Cancer Prevention 59 goserelin 59 Aflibercept 59 Randomized Study 59 Ocrelizumab 59 antitumor effect 59 assessing T DM1 59 Metastatic Colorectal Cancer 59 FOLPI 59 enoximone 59 blinded randomized placebo controlled 59 prospectively defined 59 CHAMPION PCI 59 MGd 59 AA Amyloidosis 59 metastatic renal cell 59 subanalysis 59 Trial PCPT 59 Pertuzumab 59 Cardiotoxicity 59 Clinical Antipsychotic Trials 59 axitinib 59 Solid Tumors 59 tarenflurbil 59 iniparib 59 evaluating T DM1 59 dose escalation clinical 59 Aplidin 59 phase IIb trial 59 OPT CHF 59 beta carotene supplementation 59 relapsing remitting MS RRMS 59 KRAS status 59 NO# [002] 59 Quinamed 59 Bezielle 59 registrational trial 59 Ozarelix 59 cinacalcet 59 Rezular 59 SPARCL 59 placebo controlled Phase 59 APTIVUS 59 ALLHAT 59 Hepatocellular Carcinoma 59 CoFactor 59 HIV HCV coinfected 59 Betaferon ® 59 Taxotere ® 59 Tarceva TM 59 ENESTnd 58 Metastatic Prostate Cancer 58 malignant pleural mesothelioma 58 metastatic RCC 58 afatinib 58 Phase Ib clinical 58 EORTC 58 ELACYT 58 BEXXAR Therapeutic Regimen 58 Rheumatoid Arthritis Patients 58 INCB# [003] 58 HPTN 58 alvespimycin 58 viral kinetics 58 multicentre randomized 58 Prospective Randomized 58 Carotid Revascularization Endarterectomy vs. 58 selenium supplementation 58 avosentan 58 imatinib Gleevec 58 Tavocept 58 CR# vcMMAE 58 refractory metastatic 58 Hydroxyurea 58 Prolongs Survival 58 placebo controlled clinical 58 NATRECOR ® 58 Faslodex 58 vandetanib 58 neratinib 58 tipranavir 58 Tumor Response 58 cilostazol 58 Randomized Evaluation 58 phase IIa clinical 58 Tiotropium 58 Bayer HealthCare Onyx Pharmaceuticals 58 Nesiritide 58 oral FTY# 58 Zemplar Capsules 58 mapatumumab 58 PRoFESS 58 oral deforolimus 58 trastuzumab emtansine T DM1 58 heavily pretreated 58 HRPC 58 Cohort Study MACS 58 HGPIN 58 Follicular Lymphoma 58 ExTRACT TIMI 58 antibody MAb 58 bevacizumab Avastin 58 antiangiogenic agents 58 Glufosfamide 58 interferon gamma 1b 58 Chronic Lymphocytic Leukemia 58 antioxidant supplementation 58 posaconazole 58 elotuzumab 58 Ophena TM 58 Gastric Cancer 58 Trastuzumab 58 NATRECOR R 58 stage IIIB 58 CYT# potent vascular disrupting 58 RE LY trial 58 ocrelizumab 58 RECIST Response Evaluation Criteria 58 sorafenib tablets 58 irbesartan 58 MERLIN TIMI 58 SABCS 58 multicenter Phase II 58 CombAT 58 mycophenolate mofetil 58 NEUVENGE 58 dose escalation Phase 58 double blinded placebo 58 GSK# [001] 58 teriflunomide 58 virologic response 58 tesmilifene 58 PRECiSE 58 LY# [003] 58 relapsed MCL 58 oral Xeloda 58 Sipuleucel T 58 dexpramipexole 58 trastuzumab Herceptin ® 58 dasatinib 58 CANCIDAS 58 prospective observational studies 58 MADIT CRT trial 58 MEND CABG 58 prospective multicentre 58 decitabine 58 Ovarian Cancer Screening 58 sustained virological response 58 Ceplene/IL-2 58 Renal Cell Carcinoma RCC 57 TG MV 57 APTIVUS r 57 BENICAR HCT 57 ACUITY trial 57 dose escalation phase 57 Jevtana 57 pediatric malignancies 57 tocilizumab 57 HGS ETR2 57 Bevacizumab 57 ibandronate 57 DU #b 57 recurrent GBM 57 folate supplementation 57 NSABP B 57 Intervention Trial 57 TMC# C# 57 abiraterone acetate 57 Acute Myocardial Infarction 57 EMPHASIS HF trial 57 CR nPR 57 Ranolazine 57 multicenter randomized clinical 57 randomized discontinuation trial 57 relapsed ovarian cancer 57 Pemetrexed 57 Xelox 57 ATACAND 57 phase IIb clinical 57 Virulizin ® 57 SWOG 57 Benign Prostatic Hyperplasia 57 bone metastasis 57 HGS ETR1 57 tolvaptan 57 Cardiovascular Risk 57 Phase 1b 57 pain palliation 57 APPRAISE 57 ZACTIMA 57 MDV# 57 prostate cancer CRPC 57 cilengitide 57 cetuximab Erbitux 57 Imatinib 57 GnRH agonists 57 superficial bladder cancer 57 GISSI 57 multicenter placebo controlled 57 Tarceva erlotinib 57 ximelagatran 57 Trandolapril 57 Novartis Zometa 57 apremilast 57 FASLODEX 57 androgen independent 57 metastatic hormone refractory 57 recurrent NSCLC 57 prospective randomized placebo 57 Lp PLA 2 57 PLCO trial 57 lipid lowering therapy 57 metastatic renal cell carcinoma 57 recurrent ovarian cancer 57 Lipid Lowering Treatment 57 receptor tyrosine kinase inhibitor 57 multicenter Phase 57 ancrod 57 specific antigen PSA 57 randomized Phase III 57 #F FDG PET 57 PROLARIS 57 Amrubicin 57 CARE HF 57 PRESEPT 57 Prostate Cancer Survival 57 REMINYL ® 57 VADT 57 pomalidomide 57 prucalopride 57 Wisconsin Sleep Cohort 57 HYVET 57 ACCORD Eye 57 custirsen 57 Phenoptin 57 ganetespib 57 advanced metastatic prostate 57 gefitinib 57 antiangiogenic therapy 57 phase IIIb 57 evaluating tivozanib 57 MADIT CRT 57 cabazitaxel 57 ACCORD Lipid 57 endothelin antagonists 57 ACOMPLIA R 57 ZOLINZA 57 paclitaxel poliglumex 57 hormone refractory prostate cancer 57 Diamyd r vaccine 57 ritonavir boosted 57 registrational 57 relapsed GBM 57 oral prodrug 57 Acute Ischemic Stroke 57 Phase #/#a 57 mCRC 57 ABCSG 57 NCCTG N# 57 sustained virologic response 57 SUTENT 56 RoACTEMRA 56 BARI 2D 56 Cloretazine 56 Dialysis Outcomes 56 ongoing Phase IIIb 56 Raloxifene STAR 56 PROactive study 56 CAPRIE 56 protease inhibitor PI 56 Therapeutic Effects 56 trastuzumab DM1 T DM1 56 Ovarian PLCO Cancer 56 recurrent prostate cancer 56 pegylated liposomal doxorubicin 56 cobiprostone 56 Nexavar sorafenib 56 Afatinib 56 dasatinib Sprycel ® 56 alkylating agent 56 prospective observational cohort 56 elacytarabine 56 Intervention Effectiveness CATIE 56 mCRC patients 56 Hodgkin lymphoma HL 56 DAPT 56 prostate cancer CaP 56 brivaracetam 56 pramlintide metreleptin combination 56 IMC A# 56 pancreatic adenocarcinoma 56 Phase #b/#a clinical 56 randomized controlled Phase 56 CALGB 56 iclaprim 56 biologic therapy 56 HER2 expression 56 CIMZIA TM certolizumab pegol 56 nilotinib 56 endometrial hyperplasia 56 PXD# 56 Hepatotoxicity 56 Cardiac Resynchronization 56 trastuzumab Herceptin R 56 BAY #-# 56 TEMODAL 56 Sustained Virological Response 56 Randomized Controlled Trials 56 docetaxel chemotherapy 56 cardiovascular morbidity 56 Diabetes ACCORD 56 Doxil ® 56 Irinotecan 56 randomized multicenter 56 reboxetine 56 APEX AMI trial 56 clazosentan 56 mucosal healing 56 ALISTA 56 glufosfamide 56 nonsmall cell lung cancer 56 pharmacokinetic PK study 56 BR.# 56 Hormone Receptor Positive 56 elevated LDL cholesterol 56 ASCEND HF 56 dosing cohort 56 galiximab 56 randomized multicenter Phase III 56 Invasive Breast Cancer 56 Preclinical Study 56 dose escalation trial 56 IMPACT DCM 56 Glucosamine chondroitin Arthritis 56 Phase 2b study 56 trials RCTs 56 Monotherapy 56 paricalcitol 56 Denufosol 56 degarelix 56 AVERROES 56 lapatinib Tykerb 56 AVADO 56 AIR CF1 56 trastuzumab Herceptin 56 Advaxis Phase 56 sUA 56 AEGR 56 AZILECT R 56 evaluating Xcytrin 56 symptomatic BPH 56 Severe Asthma 56 mITT population 56 dasatinib Sprycel 56 Hexvix 56 RSD# oral 56 phase IIa 56 PhG alpha 1 56 oral rivaroxaban 56 bevacizumab Avastin ® 56 Decompensated Heart Failure 56 selective modulator 56 colesevelam HCl 56 Randomized trials 56 trabedersen 56 panobinostat 56 YERVOY 56 Phase IIB 56 AIR CF2 56 lintuzumab 56 standard chemotherapy regimen 56 glatiramer acetate 56 Controlled Trial 56 placebo controlled randomized 56 VFEND 56 adenoma recurrence 56 EGFR TKI 56 KRAS variant 56 clinical pharmacology studies 56 AVASTIN 56 imetelstat 56 EURIDIS 56 Lung Cancer Survival 56 Sprycel dasatinib 56 Arranon 56 intensive statin therapy 56 Cloretazine ® 56 Polyp Prevention Trial 56 serum urate levels 56 docetaxel Taxotere ® 56 estramustine 56 Onrigin 56 KRAS mutation 56 SCCHN 56 Erlotinib 56 neurologic progression 56 sipuleucel T 56 aflibercept 56 Percutaneous Coronary Intervention 56 Scandinavian Simvastatin Survival 56 randomized multicenter trial 56 Laquinimod 56 Stage IIB 56 FOLFOX6 56 Phase 1a clinical 56 CURRENT OASIS 7 56 Venous Thromboembolism 56 CLARITY study 56 Talabostat 56 Trial NLST 56 CIMZIA TM 56 acute coronary syndromes ACS 56 NSABP C 56 multicenter multinational 56 prospective nonrandomized 56 IL# PE#QQR 56 androgen suppression 55 Dextofisopam 55 pharmacokinetic PK 55 Troxatyl 55 multicenter randomized controlled 55 TRITON TIMI 55 EVEREST II 55 invasive aspergillosis 55 Gynecologic Oncology Group 55 phase IIb 55 complete cytogenetic response 55 ASA# 55 Renal Cancer 55 NLX P# 55 lenalidomide Revlimid R 55 EUS FNA 55 colorectal adenoma 55 CLL8 55 abiraterone 55 Non inferiority 55 IFN α 55 lanthanum carbonate 55 colorectal carcinoma 55 Azacitidine 55 postoperative chemotherapy 55 PRIMO CABG 55 Clinical Outcome 55 eplerenone 55 AGILECT R 55 IMPROVE IT 55 peg interferon 55 talabostat 55 metastatic castrate resistant 55 limiting toxicity 55 refractory AML 55 orBec 55 SYMMETRY trial 55 5 Fluorouracil 55 RG# ITMN 55 insulin detemir 55 prostate cancer AIPC 55 Fludara 55 TLUS 55 secondary efficacy endpoint 55 subclinical hypothyroidism 55 Digital Mammographic Imaging 55 colorectal tumors 55 Herceptin trastuzumab 55 II Clinical Trial 55 Val HeFT 55 GOUT 55 Dendreon Provenge 55 Metastatic Breast Cancer 55 forodesine 55 Phase 2b trial 55 cancer mCRC 55 iPrEx study 55 pharmacodynamics PD 55 metastatic CRC 55 multicenter randomized placebo controlled 55 HF ACTION 55 randomized Phase IIb 55 KRN# 55 optimal dosing 55 recurrent venous thromboembolism 55 luteinizing hormone releasing 55 erlotinib Tarceva ® 55 huC# DM4 55 substudy 55 vidofludimus 55 Tesmilifene 55 lorvotuzumab mertansine 55 Outpatient Setting 55 Levels Linked 55 regorafenib 55 controlled multicenter 55 ELCAP 55 Cervical Dysplasia 55 multicenter phase 55 IMGN# 55 canakinumab 55 intravesical therapy 55 GnRH agonist 55 severe oral mucositis 55 rosuvastatin #mg 55 oral ridaforolimus 55 metastatic colorectal cancer 55 Screening Trial 55 ALSYMPCA 55 Patient Outcomes 55 grade cervical intraepithelial 55 ARIXTRA 55 SCD HeFT 55 medically inoperable 55 registrational Phase 55 resistant ovarian cancer 55 IRX 2 55 nonrandomized 55 panitumumab Vectibix 55 COPERNICUS 55 evaluating REVLIMID 55 Secondary efficacy endpoints 55 LHRH agonists 55 dosing regimens 55 epithelial tumors 55 BOLDER II 55 PROSTVAC VF 55 Heart Failure Trial 55 Thromboembolism 55 antihypertensive therapy 55 Response Evaluation Criteria 55 landmark ATHENA 55 Xinlay 55 Statistically Significant 55 randomized clinical 55 multiple myeloma MM 55 Phase Ib 55 Hematological 55 ovarian carcinoma 55 Cipralex ® 55 BMC Musculoskeletal Disorders 55 metastatic HRPC 55 pivotal bioequivalence 55 NCT# ClinicalTrials.gov 55 eosinophilic asthma 55 Glucosamine Chondroitin Arthritis 55 REYATAZ r 55 hormone receptor negative 55 trabectedin 55 Corus CAD 55 SORT OUT III 55 Subgroup analyzes 55 Neulasta ® 55 CALERIE 55 preoperative chemotherapy 55 Preterm Delivery 55 plasma pharmacokinetics 55 advanced metastatic renal 55 Bivalirudin 55 ERSPC 55 angiogenesis inhibitor 55 relapsed SCLC 55 vismodegib 55 alvimopan 55 fosbretabulin 55 Bortezomib 55 MEND CABG II 55 TAXUS IV 55 chemoradiotherapy 55 RECORD1 55 COPAXONE R 55 Dacogen injection 55 recurrent metastatic 55 Rosuvastatin 55 mixed hyperlipidemia 55 prostate carcinogenesis 55 ASTEROID 55 phase IIb study 55 sunitinib 55 neoadjuvant 55 Phase III placebo controlled 55 STICH trial 55 antiplatelet therapy 55 platinum refractory 55 clinically localized prostate 55 Allovectin 7 55 TORISEL 55 randomized controlled clinical 55 liver transplant recipients 55 TARGIT 55 Shows Efficacy 54 Zerenex 54 EFAPROXYN 54 bone metastases 54 node metastases 54 Targretin 54 Randomized controlled 54 Avastin bevacizumab 54 hepatocellular carcinoma 54 Hedgehog Pathway Inhibitor 54 ACOSOG Z# 54 Phase III randomized controlled 54 cytogenetic response 54 refractory CLL 54 serum uric acid 54 multicenter trials 54 Overactive Bladder OAB 54 atherothrombotic disease 54 CML CP 54 Cardiac Allograft Rejection 54 lumiliximab 54 Phase IIIb 54 oral PrEP 54 dose cohort 54 placebo controlled trials 54 maximally tolerated dose 54 EndoTAGTM 1 54 invasive candidiasis 54 STEP BD 54 cisplatin resistant 54 LHRH receptor positive 54 pharmacokinetic PK profile 54 LymphoStat B 54 Zarnestra 54 CRESTOR #mg 54 cetrorelix 54 non squamous NSCLC 54 Adjuvant chemotherapy 54 urate levels 54 ARCOXIA 54 ascending dose 54 serum GGT 54 prostate cancer PCa 54 rALLy trial 54 Prostate Cancer Outcomes 54 HBeAg seroconversion 54 LIALDA 54 BRAF mutation 54 strontium ranelate 54 virologic failure 54 RE MODEL 54 Intervention Effectiveness 54 resected pancreatic cancer 54 ACCOMPLISH 54 alpha 2a 54 ABSORB trial 54 Sorafenib 54 AIR CF3 54 concurrent chemoradiation 54 morphometric vertebral fractures 54 OncoVEX GM CSF 54 pegylated interferon alfa 2b 54 multicenter clinical 54 chlamydial infection 54 Alemtuzumab 54 gastrointestinal stromal tumors GIST 54 pegfilgrastim 54 Amigal 54 TRISENOX 54 FDG PET 54 ORMD 54 dyslipidaemia 54 European Randomized Study 54 antiplatelet agent 54 locoregional recurrence 54 chromium supplementation 54 HER2 overexpression 54 CHARISMA trial 54 Subgroup Analysis 54 prospective multicenter study 54 Breast Density 54 TDF FTC 54 PCa 54 edoxaban 54 Phase IIIb study 54 HORIZONS AMI trial 54 methodologically rigorous 54 IRESSA 54 Iressa gefitinib 54 imatinib therapy 54 elevated CRP 54 sitaxsentan 54 Torisel 54 RIO Lipids 54 GAMMAGARD 54 ICON7 54 BEIR 54 homocysteine concentrations 54 composite endpoint 54 LEXIVA r 54 rosuvastatin Crestor 54 idraparinux 54 neoadjuvant treatment 54 Randomised 54 noninfectious uveitis 54 secondary endpoint 54 Hycamtin 54 Natalizumab 54 adalimumab 54 Corlux 54 Phase Ia 54 noscapine 54 Fludara ® 54 ozarelix 54 comparator arm 54 CIPN 54 Forodesine HCl 54 iPTH 54 desvenlafaxine succinate 54 virological response 54 SPIRIT IV 54 eculizumab therapy 54 Left Ventricular Dysfunction 54 serum clusterin levels 54 PEGylated interferon beta 1a 54 lixisenatide 54 Uterine Cancer 54 MVA MUC1 IL2 54 relapsed refractory multiple myeloma 54 tolerated dose MTD 54 intravenous bisphosphonates 54 ADMIRE HF 54 romiplostim 54 Multiple Myeloma Patients 54 milatuzumab 54 radiochemotherapy 54 visilizumab 54 placebo controlled dose escalation 54 Statin Drugs 54 ongoing Phase 1b 54 Infarct 54 achieved ACR# 54 randomized controlled clinical trials 54 adjuvant therapy 54 ECTRIMS 54 neoadjuvant therapy 54 dacetuzumab 54 randomized multicentre 54 alkylating agents 54 Sutent sunitinib 54 Lung Cancer Drug 54 XIENCE V PROMUS Stent 54 ELND# 54 PRADAXA 54 ginkgo biloba extract 54 noninferiority 54 Myocardial Infarction Study 54 PROMACTA 54 BENICAR 54 ENDEAVOR IV 54 Combination Treatment 54 adjuvant radiation 54 SCH # 54 intravenous dosing 54 T#I [002] 54 Improves Survival 54 tyrosine kinase inhibitor 54 depsipeptide 54 colorectal liver metastases 54 Ixempra 54 ELOXATIN 54 metastatic CRPC 54 Prospective Randomized Trial 54 Triapine R 54 mg/m2 dose 54 pelvic lymphadenectomy 54 Gefitinib 54 placebo controlled Phase III 54 ADAGIO study 54 adjuvant trastuzumab 54 non inferiority 54 HER2 positive breast cancer 54 PANVAC VF 54 cell lymphoma CTCL 54 Gleevec resistant 54 atypical ductal hyperplasia 54 Selective Internal 54 bendamustine 54 mg BID dose 54 VIDAZA 54 LUMINATE 54 Zolinza 54 Ceflatonin 54 adjuvant therapies 54 Adalimumab 54 PREVENT IV 54 ULORIC 54 valopicitabine 54 KRAS mutations occur 54 CTA# Injection 54 PFO migraine 54 CIN2 + 54 Phase III VISTA 54 F FDG PET 54 CARDIA study 54 alteplase 54 oral methylnaltrexone 54 aldosterone antagonists 54 ASPIRE HIGHER 54 anti angiogenic therapy 54 INC# 54 unfractionated heparin UFH 54 CETP inhibition 54 PREZISTA r 54 colorectal adenomas 54 Phase IIa trial 54 Metastatic 54 confirmatory clinical 54 REVIVE Diabetes 54 plus dexamethasone 54 mITT 54 lupus nephritis 54 refractory multiple myeloma 54 DLTs 54 MoxDuo TM IR 54 Phase III AFFIRM 53 PRE SURGE 53 CLARITY TIMI 53 oblimersen 53 prospectively stratified 53 pancreatic carcinoma 53 Revlimid lenalidomide 53 carboplatin paclitaxel 53 Multicenter AIDS 53 Phase 1b trial 53 Solid Tumours 53 PSADT 53 NSCLC 53 pazopanib 53 certolizumab 53 achieved sustained virological 53 non metastatic osteosarcoma 53 lipid lowering drugs 53 leukemia ALL 53 rituximab Rituxan 53 Mimpara 53 catheter occlusion 53 Clinical Outcomes Utilizing Revascularization 53 IFN alfa 53 Prevent Heart 53 AP# [003] 53 opioid induced bowel dysfunction 53 Roche Xeloda 53 IASLC 53 eltrombopag 53 virologic 53 atherogenic dyslipidemia 53 stage IIIb IV 53 recurrent malignant glioma 53 levosimendan 53 HORIZONS AMI 53 Clinical Trial Evaluating 53 HeFT 53 Alpha Tocopherol Beta Carotene 53 Folfox 53 SPIRIT FIRST 53 operable breast cancer 53 number NCT# ClinicalTrials.gov 53 pharmacokinetics PK 53 EGFR mutations 53 peginterferon alfa 2a 53 Androxal TM 53 tolerability pharmacokinetics 53 refractory prostate cancer 53 serum phosphorous 53 Randomized Clinical Trial 53 nucleoside analogue 53 Zevalin consolidation 53 pharmacokinetic equivalence 53 candesartan cilexetil 53 vemurafenib 53 retrospective cohort 53 null responder HCV 53 eGFR 53 myelodysplastic syndromes MDS 53 estimated GFR 53 ACR# responses 53 EVIZON 53 icatibant 53 rolofylline 53 Intracranial Aneurysms 53 RESIST studies 53 docetaxel Taxotere 53 adjuvant radiotherapy 53 venlafaxine XR 53 advanced hepatocellular carcinoma 53 Drug Prevents 53 multicentre 53 HOPE TOO 53 B CLL 53 Clinicaltrials.gov 53 HGS# 53 prospective observational 53 Vectibix 53 panitumumab 53 β blockers 53 Iron Deficiency 53 nonfatal MI 53 paclitaxel eluting stents 53 Gleevec imatinib 53 Everolimus 53 CUSTOM III 53 QNEXA 53 hematopoietic cancers 53 cabozantinib 53 randomized blinded 53 paclitaxel carboplatin